cytarabine

An antimetabolite drug used in the treatment of acute LEUKAEMIA. It is a purine antagonist (see PURINES) and acts by depriving cells of essential metabolic substances. It causes sickness and vomiting, peptic ulcers and depression of bone marrow blood formation. The drug is on the WHO official list. A brand name is Cytosar.

cytarabine

an antimetabolite that inhibits DNA synthesis, and hence has antineoplastic and antiviral properties. Called also cytosine arabinoside, arabinosyl cytosine, ara-C.

The results were based on a subgroup analysis, after 12 months of follow-up, in a randomized Phase 2b trial that compared CPX-351 to conventional cytarabine and daunorubicin (7+3 regimen), the current standard of care (ASCO Abstract #6519).

The financial support provided by the LLS Therapy Acceleration Program (TAP) has been important in expediting the completion of the Phase 3, multicenter trial of CPX-351 versus conventional cytarabine plus daunorubicin in older patients with untreated high risk (secondary) AML.

The trial evaluated the addition of either PKC412 (midostaurin) or placebo to daunorubicin/cytarabine in the induction phase, followed by high-dose cytarabine in the consolidation phase; patients who achieved complete remission after consolidation chemotherapy continued treatment with PKC412 (midostaurin) or placebo as a single agent for up to one year[sup.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.